For families who have ever sat through a post-surgery cancer prognosis, the FDA delivered rare good news on October 8: it approved atezolizumab, sold as Tecentriq by Genentech, combined with standard chemotherapy as an after-surgery treatment for Stage III mismatch repair deficient colon cancer. It is the first immunotherapy-based regimen ever cleared for this setting, and Genentech expects it to become the new standard of care.
The approval covers adults and children aged two and older. In the same move, the agency cleared Tecentriq Hybreza, a subcutaneous version, for patients 12 and up. That matters more than it sounds: eligible patients can now get the immunotherapy as an under-the-skin injection instead of spending hours on an IV infusion.
The trial behind the decision
The decision rests on the Phase 3 ATOMIC trial, published in The New England Journal of Medicine. It enrolled 711 adults plus one pediatric patient with Stage III dMMR colon cancer after complete tumor removal. One group received atezolizumab with the standard mFOLFOX6 chemotherapy for 12 cycles, followed by six more months of atezolizumab alone. The other got chemotherapy alone.
The result: the combination cut the risk of the cancer returning or of death by 50 percent, a hazard ratio of 0.50 with a p-value of 0.0001. After a median follow-up of about 41 months, three-year disease-free survival stood at 86.3 percent with the combination versus 76.2 percent with chemotherapy alone. The advantage held across node stage, tumor stage, and tumor location, and it survived a per-protocol analysis of 600 patients.
Why these tumors listen to immunotherapy
Mismatch repair is the cell’s spell-check for copying DNA. When the system is deficient, mutations pile up fast, and the tumor ends up covered in abnormal proteins that look foreign to the immune system. Atezolizumab, a PD-L1 inhibitor, works by releasing the brakes on that immune response. In tumors already waving red flags at the immune system, taking the brakes off can be dramatic.
This is precision medicine in its cleanest form: match the treatment to the tumor’s biology instead of treating every colon cancer the same way. Frank A. Sinicrope of the Mayo Clinic, the U.S. principal investigator for the Alliance ATOMIC trial, noted that until now the post-surgery standard of care did not differ by mismatch repair status. That era is over.
Three things this changes for patients
First, the prognosis conversation. Roughly a quarter of colon cancers are diagnosed at Stage III, and nearly one in three Stage III patients see the cancer return within five years. Anyone with a dMMR tumor, and testing is now more important than ever, should ask about this regimen. Those already in treatment should talk with their care team before changing anything.
Second, the practical quality of life. Infusions devour hours of a patient’s week. A single injection is a different experience entirely, and small conveniences compound when you are recovering from surgery.
Third, the momentum. This is Tecentriq’s twelfth U.S. indication. The drug keeps expanding across cancer types, and each expansion sharpens oncologists’ sense of where immunotherapy works best.
Progress in cancer care rarely arrives as a single dramatic cure. More often it arrives like this: a well-run trial, a risk halved, a new standard, and thousands of families who get to breathe a little easier. This week, that is exactly what happened.
Be First to Comment